×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder
Become an Incathlab member and receive full access to its content!
You must be an Incathlab member to access videos without any restrictions. Register for free in one minute and access all services provided by Incathlab.You will also be able to log into Incathlab from your Facebook or twitter account by clicking on login on the top-right corner of Incathlab website.
Registration Login
Registration Login
Clinical Data
- Patient: Male, 78 years old
- Known CAD with inferior STEMI 2000 (lysis)
- PCI of CX march 2000 (BMS)
- PCI of LAD may 2000 (BMS)
- LVEF 40%, inferior and lateral akinesia
- CVRF: hypertension, dyslipidemia
- Progressive Dyspnea NYHA III
- CAG 9.8.17: very calcified vessels, proximal LAD in stent <30%, mid LAD 50%, CX with good result in-stent, RCA with several severe stenosis
- Echo: LVEF 40%, Afib; inferior and lateral akinesia, moderate to severe MR
- Renal function: eGFR = 62 ml/min/1.73m2
- Hemodynamics: no pulmonary hypertension, mPAP = 24 mmHg, PCWP = 10 mmHg
Shooting date : 2017-09-12
Last update : 2017-10-31
Last update : 2017-10-31
SeQuent® Please NEO / B. Braun
Next generation coronary Drug Coated Balloon to treat vascular stenosis
OptiRAY® / Guerbet
Optiray® contrast agent is lower osmolar, lower viscosity and nonionic.
Join the Discussion
Suggestions
Wednesday, July 5th 2023 from 06pm to 07pm (GMT+2)
Honolulu : Wednesday, July 5th 2023 from 06am to 07am (GMT+2)
San Francisco : Wednesday, July 5th 2023 from 09am to 10am (GMT+2)
New York : Wednesday, July 5th 2023 from 12pm to 01pm (GMT+2)
Buenos Aires : Wednesday, July 5th 2023 from 01pm to 02pm (GMT+2)
Reykjavik : Wednesday, July 5th 2023 from 04pm to 05pm (GMT+2)
London / Dublin : Wednesday, July 5th 2023 from 05pm to 06pm (GMT+2)
Paris / Berlin : Wednesday, July 5th 2023 from 06pm to 07pm (GMT+2)
Istanbul : Wednesday, July 5th 2023 from 07pm to 08pm (GMT+2)
Moscou / Dubaï : Wednesday, July 5th 2023 from 08pm to 09pm (GMT+2)
Bangkok : Wednesday, July 5th 2023 from 11pm to 12am (GMT+2)
Shanghai : Thursday, July 6th 2023 from 12am to 01am (GMT+2)
Tokyo : Thursday, July 6th 2023 from 01am to 02am (GMT+2)
Sydney : Thursday, July 6th 2023 from 03am to 04am (GMT+2)
Wellington : Thursday, July 6th 2023 from 05am to 06am (GMT+2)
San Francisco : Wednesday, July 5th 2023 from 09am to 10am (GMT+2)
New York : Wednesday, July 5th 2023 from 12pm to 01pm (GMT+2)
Buenos Aires : Wednesday, July 5th 2023 from 01pm to 02pm (GMT+2)
Reykjavik : Wednesday, July 5th 2023 from 04pm to 05pm (GMT+2)
London / Dublin : Wednesday, July 5th 2023 from 05pm to 06pm (GMT+2)
Paris / Berlin : Wednesday, July 5th 2023 from 06pm to 07pm (GMT+2)
Istanbul : Wednesday, July 5th 2023 from 07pm to 08pm (GMT+2)
Moscou / Dubaï : Wednesday, July 5th 2023 from 08pm to 09pm (GMT+2)
Bangkok : Wednesday, July 5th 2023 from 11pm to 12am (GMT+2)
Shanghai : Thursday, July 6th 2023 from 12am to 01am (GMT+2)
Tokyo : Thursday, July 6th 2023 from 01am to 02am (GMT+2)
Sydney : Thursday, July 6th 2023 from 03am to 04am (GMT+2)
Wellington : Thursday, July 6th 2023 from 05am to 06am (GMT+2)
Left Main and Bifurcation treatment:
impact of clinical trials in daily practice
Share
Thursday, September 14th 2017 from 01pm to 02:30pm (GMT+2)
Honolulu : Thursday, September 14th 2017 from 01am to 02:30am (GMT+2)
San Francisco : Thursday, September 14th 2017 from 04am to 05:30am (GMT+2)
New York : Thursday, September 14th 2017 from 07am to 08:30am (GMT+2)
Buenos Aires : Thursday, September 14th 2017 from 08am to 09:30am (GMT+2)
Reykjavik : Thursday, September 14th 2017 from 11am to 12:30pm (GMT+2)
London / Dublin : Thursday, September 14th 2017 from 12pm to 01:30pm (GMT+2)
Paris / Berlin : Thursday, September 14th 2017 from 01pm to 02:30pm (GMT+2)
Istanbul : Thursday, September 14th 2017 from 02pm to 03:30pm (GMT+2)
Moscou / Dubaï : Thursday, September 14th 2017 from 03pm to 04:30pm (GMT+2)
Bangkok : Thursday, September 14th 2017 from 06pm to 07:30pm (GMT+2)
Shanghai : Thursday, September 14th 2017 from 07pm to 08:30pm (GMT+2)
Tokyo : Thursday, September 14th 2017 from 08pm to 09:30pm (GMT+2)
Sydney : Thursday, September 14th 2017 from 10pm to 11:30pm (GMT+2)
Wellington : Friday, September 15th 2017 from 12am to 01:30am (GMT+2)
San Francisco : Thursday, September 14th 2017 from 04am to 05:30am (GMT+2)
New York : Thursday, September 14th 2017 from 07am to 08:30am (GMT+2)
Buenos Aires : Thursday, September 14th 2017 from 08am to 09:30am (GMT+2)
Reykjavik : Thursday, September 14th 2017 from 11am to 12:30pm (GMT+2)
London / Dublin : Thursday, September 14th 2017 from 12pm to 01:30pm (GMT+2)
Paris / Berlin : Thursday, September 14th 2017 from 01pm to 02:30pm (GMT+2)
Istanbul : Thursday, September 14th 2017 from 02pm to 03:30pm (GMT+2)
Moscou / Dubaï : Thursday, September 14th 2017 from 03pm to 04:30pm (GMT+2)
Bangkok : Thursday, September 14th 2017 from 06pm to 07:30pm (GMT+2)
Shanghai : Thursday, September 14th 2017 from 07pm to 08:30pm (GMT+2)
Tokyo : Thursday, September 14th 2017 from 08pm to 09:30pm (GMT+2)
Sydney : Thursday, September 14th 2017 from 10pm to 11:30pm (GMT+2)
Wellington : Friday, September 15th 2017 from 12am to 01:30am (GMT+2)
How should I treat complex anatomic lesions and manage complications?
Interactive discussion with your experts - Rotablator & CTO
Share
Henry K. Thank you for showing this fastastic and successful case, I was wondering about if there is a lot of evidence supporting avoiding stenting the whole mid RCA by using DEB especially when there is not much marginal branches to worry about.
Ahmed S. excellent results for this heavily diseased and calcified artery